Zhejiang Cancer Hospital Zhejiang Cancer Research Institute

Hangzhou, China

Zhejiang Cancer Hospital Zhejiang Cancer Research Institute

Hangzhou, China

Time filter

Source Type

Tao K.-Y.,Zhejiang Cancer Hospital Zhejiang Cancer Research Institute | Li X.-X.,Zhejiang Cancer Hospital Zhejiang Cancer Research Institute | Xu W.-Z.,China Institute of Technology | Wang Y.,Zhejiang Provincial Peoples Hospital | And 6 more authors.
OncoTargets and Therapy | Year: 2015

Background: Single-nucleotide polymorphisms in apoptosis-related genes have been shown to play a role in the efficacy of platinum-based chemotherapy and may influence clinical outcomes. Our study aimed to evaluate the correlations of four functional single-nucleotide polymorphisms - FAS -670 A>G, FAS ligand -844 T>C, survivin -31 G>C, and survivin 9386 C>T – with drug response and clinical outcomes in advanced non-small-cell lung cancer patients who received platinum-based chemotherapy.Materials and methods: Polymorphisms were evaluated using the polymerase chain reaction-based restriction fragment-length polymorphism technique.Results: Patients with the CC genotype of FAS -670 A>G had worse overall survival (OS) than those with the CT or TT genotype (P=0.044), with median OS values of 20.1 months, 22.8 months, and 26.0 months, respectively. Furthermore, progression-free survival was associated with the FAS -670 A>G polymorphism (P=0.032). In addition, patients with the TC and CC genotypes of survivin 9386 C>T experienced improved survival compared with patients with the TT genotype (median OS 31.4 months and 22.8 months, respectively).Conclusion: The functional FAS -670 A>G and survivin 9386 C>T polymorphisms are potential independent prognostic factors in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. © 2015 Tao et al.


PubMed | China Institute of Technology, Zhejiang Cancer Hospital Zhejiang Cancer Research Institute and Zhejiang Cancer Hospital
Type: Journal Article | Journal: Journal of cancer research and therapeutics | Year: 2016

To observe the efficacy and toxicities of combined nimotuzumab with chemoradiotherapy as the first-line treatment to advanced esophageal squamous cell carcinoma (ESCC).The clinical data of 43 patients with local advanced or metastatic ESCC treated with nimotuzumab combined with chemoradiotherapy in our hospital were included in this retrospective study. The overall response, adverse events, overall survival (OS), and progressive-free survival (PFS) were analyzed.At 1 month after the treatment, objective response rate (complete response [CR] + partial response [PR]) was 65.12%, and disease control rate (CR + PR + stable disease [SD]) was 86.05%, with one patient (2.33%) showing CR, 27 (62.79%) patients with PR, 9 (20.93%) with SD, and 6 (13.95%) with progressive disease, respectively. The median OS was 15.5 months, and the median PFS was 8.83 months. Multivariate analysis showed that the patients with more cycles (>6 times) of nimotuzumab treatment had better PFS and OS than those with fewer cycles (6 times). Patients received high-dose radiation (>55 Gy) had a better PFS than those patients received low-dose radiation (55 Gy). Three patients suffered severe esophageal fistula, and three patients showed superficial skin erosion.Chemoradiotherapy in combination with more than 6 weekly doses of nimotuzumab (>1400 mg) had a survival benefit to the patients with advanced ESCC. High-dose radiation therapy for primary tumor has been confirmed to improve PFS in these patients. Patients treated with nimotuzumab showed no increased risk of adverse events.


Zheng Z.-G.,Zhejiang Cancer Hospital Zhejiang Cancer Research Institute | Yu H.-Q.,Rockefeller University | Ling Z.-Q.,Zhejiang Cancer Hospital Zhejiang Cancer Research Institute | Mou H.-Z.,Zhejiang Cancer Hospital Zhejiang Cancer Research Institute | And 2 more authors.
Protein and Peptide Letters | Year: 2011

Mass spectrometric profiling using ProteinChip and magnetic beads has rapidly grown over the past years, particularly to generate serum profiles for cancer diagnosis. The molecular weights of these distinguishing peaks are usually under 30 kDa. To identify those low molecular weight proteins and peptides is important for specific assays to be developed and increases biological insight. In this study, low molecular weight proteins and peptides from serum were purified by a combination of weak cation exchange magnetic beads and high performance liquid chromatography. The purified proteins and peptides were analyzed by 1D SDS PAGE, SELDI and LC-MS/MS. 246 proteins were identified from the HPLC fractions by LC-MS/MS. 95(38.62%) proteins were first identified in serum compare with Sys-BodyFluid database. 11(11/96) proteins were documented cancer associated proteins. We also observed about 109 proteins/peptides in SELDI mass spectrum, and 13 of the SELDI features were identified. Copyright © 2011 Bentham Science Publishers Ltd.


PubMed | Zhejiang Cancer Hospital Zhejiang Cancer Research Institute
Type: Journal Article | Journal: Protein and peptide letters | Year: 2011

Mass spectrometric profiling using ProteinChip and magnetic beads has rapidly grown over the past years, particularly to generate serum profiles for cancer diagnosis. The molecular weights of these distinguishing peaks are usually under 30 kDa. To identify those low molecular weight proteins and peptides is important for specific assays to be developed and increases biological insight. In this study, low molecular weight proteins and peptides from serum were purified by a combination of weak cation exchange magnetic beads and high performance liquid chromatography. The purified proteins and peptides were analyzed by 1D SDS PAGE, SELDI and LC-MS/MS. 246 proteins were identified from the HPLC fractions by LC-MS/MS. 95(38.62%) proteins were first identified in serum compare with Sys-BodyFluid database. 11(11/96) proteins were documented cancer associated proteins. We also observed about 109 proteins/peptides in SELDI mass spectrum, and 13 of the SELDI features were identified.

Loading Zhejiang Cancer Hospital Zhejiang Cancer Research Institute collaborators
Loading Zhejiang Cancer Hospital Zhejiang Cancer Research Institute collaborators